Hims & Hers Health (NYSE:HIMS) Price Target Cut to $33.00 by Analysts at Citigroup

Hims & Hers Health (NYSE:HIMS) had its price objective decreased by equities research analysts at Citigroup from $35.00 to $33.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the stock. Citigroup’s target price would suggest a potential upside of 6.70% from the stock’s current price.

HIMS has been the topic of several other reports. Barclays increased their price target on shares of Hims & Hers Health from $29.00 to $39.00 and gave the company an “overweight” rating in a research report on Wednesday, June 17th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Bank of America boosted their price objective on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday. Truist Financial upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Friday, July 24th. Finally, Wall Street Zen lowered shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $32.43.

Hims & Hers Health Stock Performance

NYSE HIMS traded down $0.84 on Tuesday, reaching $30.93. The stock had a trading volume of 18,796,260 shares, compared to its average volume of 26,787,123. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. Hims & Hers Health has a 12-month low of $13.74 and a 12-month high of $65.30. The business’s 50-day moving average price is $31.94 and its 200 day moving average price is $26.07. The stock has a market cap of $7.16 billion, a P/E ratio of -348.00, a price-to-earnings-growth ratio of 88.90 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.89 million. During the same period in the prior year, the company earned $0.17 earnings per share. The firm’s revenue was up 38.2% on a year-over-year basis. As a group, equities analysts expect that Hims & Hers Health will post 0.03 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, CFO Oluyemi Okupe sold 7,163 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $36.49, for a total value of $261,377.87. Following the completion of the transaction, the chief financial officer directly owned 284,321 shares in the company, valued at approximately $10,374,873.29. The trade was a 2.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Patrick Harrison Carroll sold 23,726 shares of Hims & Hers Health stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total value of $830,410.00. Following the completion of the sale, the insider directly owned 181,861 shares in the company, valued at $6,365,135. This represents a 11.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 83,126 shares of company stock valued at $2,711,339. Corporate insiders own 11.76% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of HIMS. Bank of America Corp DE increased its position in Hims & Hers Health by 194.4% during the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock worth $90,465,000 after buying an additional 2,877,550 shares during the period. Norges Bank bought a new position in Hims & Hers Health during the fourth quarter worth about $62,153,000. Invesco Ltd. raised its stake in Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock worth $235,525,000 after purchasing an additional 1,600,004 shares in the last quarter. Marex Group plc increased its holdings in shares of Hims & Hers Health by 162.2% during the fourth quarter. Marex Group plc now owns 2,419,518 shares of the company’s stock worth $78,562,000 after purchasing an additional 1,496,707 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after buying an additional 1,407,651 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Second-quarter revenue rose 38% year over year to $753.2 million, exceeding analysts’ expectations of approximately $699 million. Strong subscriber growth and broader personalized-care offerings supported the result. Hims & Hers raises annual forecast revenue on strong subscriber growth
• Positive Sentiment: Hims & Hers raised its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion, while third-quarter revenue guidance of $880 million-$900 million also topped consensus. Management cited AI-driven engagement, specialty care expansion and international growth through Eucalyptus. HIMS Q2 Earnings Call Focuses on AI and Global Expansion
• Positive Sentiment: Needham raised its price target from $35 to $42 and maintained a “buy” rating, pointing to potential upside if the company’s growth investments translate into improved profitability. Needham price target update
• Neutral Sentiment: Bank of America increased its target from $30 to $32 but retained a “neutral” rating, indicating limited near-term upside at recent trading levels. Bank of America price target update
• Negative Sentiment: The company reported a quarterly loss of approximately $0.37 per share, substantially worse than the roughly $0.05 expected loss. Restructuring charges and investments related to branded GLP-1 weight-loss treatments and international expansion pressured profitability and reduced gross margin. Hims & Hers shares slide as costly weight-loss push squeezes margins
• Negative Sentiment: Several law firms announced investigations into potential securities-law violations or alleged fiduciary-duty breaches involving Hims & Hers directors and officers. These announcements do not establish wrongdoing but add headline and litigation risk for shareholders. Kaplan Fox investigation announcement

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.